BHVN Biohaven Pharmaceutical Holding Company Ltd. Stock Quote

BHVN [NYSE]

Biohaven Pharmaceutical Holding Company Ltd.

Index	-	P/E	-	EPS (ttm)	-11.85	Insider Own	0.20%	Shs Outstand	70.33M	Perf Week	-0.40%
Market Cap	10.29B	Forward P/E	-	EPS next Y	-5.42	Insider Trans	-8.70%	Shs Float	61.72M	Perf Month	0.87%
Income	-790.70M	PEG	-	EPS next Q	-2.58	Inst Own	91.10%	Short Float	6.57%	Perf Quarter	22.93%
Sales	737.50M	P/S	13.95	EPS this Y	-0.30%	Inst Trans	1.20%	Short Ratio	2.33	Perf Half Y	5.24%
Book/sh	-6.57	P/B	-	EPS next Y	55.70%	ROA	-71.50%	Target Price	153.56	Perf Year	49.67%
Cash/sh	8.46	P/C	17.08	EPS next 5Y	-	ROE	141.00%	52W Range	79.01 - 151.51	Perf YTD	4.80%
Dividend	-	P/FCF	-	EPS past 5Y	-38.00%	ROI	-168.90%	52W High	-4.68%	Beta	1.11
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	-	Gross Margin	85.70%	52W Low	82.79%	ATR	1.27
Employees	928	Current Ratio	2.00	Sales Q/Q	628.10%	Oper. Margin	-70.80%	RSI (14)	63.13	Volatility	0.89% 0.83%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	30.40%	Profit Margin	-	Rel Volume	0.49	Prev Close	144.01
Shortable	Yes	LT Debt/Eq	-	Earnings	May 11 BMO	Payout	-	Avg Volume	1.74M	Price	144.42
Recom	2.00	SMA20	-0.09%	SMA50	12.48%	SMA200	13.85%	Volume	851,084	Change	0.28%

May-11-22

Downgrade

SVB Leerink

Outperform → Mkt Perform

$150

Oct-19-21

Resumed

Morgan Stanley

Equal-Weight

$107 → $145

Aug-10-21

Downgrade

UBS

Buy → Neutral

$108 → $109

Aug-03-21

Reiterated

Canaccord Genuity

Buy

$101 → $150

Mar-11-21

Initiated

UBS

Buy

$108

Dec-15-20

Initiated

H.C. Wainwright

Buy

$121

Apr-17-20

Initiated

Cowen

Outperform

$45

Feb-10-20

Downgrade

Oppenheimer

Outperform → Perform

Feb-06-20

Initiated

Mizuho

Buy

Nov-22-19

Initiated

Wedbush

Outperform

Jun-25-19

Reiterated

Canaccord Genuity

Buy

$89 → $84

May-06-19

Initiated

Goldman

Buy

$92

Apr-09-19

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Mar-04-19

Reiterated

Needham

Buy

$48 → $56

Jul-03-18

Reiterated

Needham

Buy

$36 → $48

Jul-02-18

Reiterated

Needham

Buy

$36 → $48

Apr-05-18

Downgrade

Barclays

Overweight → Equal Weight

$30 → $25

Feb-22-18

Reiterated

Canaccord Genuity

Buy

$30 → $39

Dec-15-17

Initiated

Canaccord Genuity

Buy

$30

Oct-03-17

Reiterated

Needham

Buy

$43 → $36

Jun-27-22 08:52AM	Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar? Zacks
Jun-22-22 10:32AM	AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention Zacks
Jun-13-22 07:30AM	Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray PR Newswire
Jun-09-22 11:30AM	Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue? Zacks
07:30AM	Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society PR Newswire
May-24-22 12:25PM	Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Is Breakeven Near? Simply Wall St.
11:13AM	Biogen Needs a New CEO. Here Are Some Options. Barrons.com
09:47AM	Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA Zacks
May-23-22 10:54AM	Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study Benzinga
07:46AM	UPDATE 2-Biohaven's drug for neurological disease fails late-stage study Reuters
07:30AM	US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine PR Newswire
07:15AM	Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA) PR Newswire
May-13-22 08:42AM	The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical Zacks
08:10AM	Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update Zacks
May-12-22 04:56PM	Pfizer Turns to Unusual Deal Structure to Buy Biohaven Drugs Bloomberg
09:11AM	Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News Zacks
May-11-22 02:12PM	Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider Zacks
01:16PM	Pfizer's $11.6 billion Biohaven buy could spark more biotech deals Reuters
01:12PM	Pfizer's $11.6 bln Biohaven buy could spark more biotech deals Reuters
May-10-22 09:00PM	Pfizer is Acquiring a Migraine Fixer for $11.6 Billion Motley Fool +68.39%
04:19PM	Nasdaq Leads Upside As Indexes Pull Back Into The Close; This Dow Jones Stock Nears Buy Point Investor's Business Daily
04:06PM	Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time' Investor's Business Daily
03:41PM	10 Stocks Making Headlines Today Insider Monkey
02:26PM	Pfizer Is Spending $11.6 Billion on Biohaven. Its Plans Point to a Lot More M&A. Barrons.com
12:06PM	Pfizer to Buy Rest of Biohaven for $11.6 Billion The Wall Street Journal
12:04PM	Stock Market Fades, Mixed At Midday; A Defensive Group Sells Off Investor's Business Daily
11:33AM	Pfizer to Acquire Biohaven Pharmaceutical for $11.6 Billion Bloomberg
10:06AM	Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion Barrons.com
09:51AM	Pfizer acquires Biohaven for $11.6 billion in cash Yahoo Finance Video
08:05AM	Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	UPDATE 1-Pfizer to buy Biohaven Pharmaceutical in $11.6 bln deal Reuters
06:56AM	Pfizer to pay $11.6 billion for Biohaven to tap migraine market Reuters
06:56AM	Pfizer to acquire Biohaven Pharma for $11.6 billion in cash sending Biohaven shares up 74% premarket MarketWatch
06:50AM	Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments PR Newswire
06:45AM	Pfizer to Acquire Biohaven Pharmaceuticals Business Wire
May-09-22 07:30AM	Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022 PR Newswire -7.88%
May-06-22 09:18AM	Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season? Zacks -6.31%
May-05-22 05:35PM	OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates Zacks
May-02-22 03:00PM	Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Apr-27-22 06:45AM	Pfizer and Biohavens VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine Business Wire
Apr-14-22 04:30PM	Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability PR Newswire
07:30AM	Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update PR Newswire
Apr-08-22 08:27AM	Those who invested in Biohaven Pharmaceutical Holding (NYSE:BHVN) three years ago are up 151% Simply Wall St.
Apr-07-22 07:30AM	Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis PR Newswire
Apr-06-22 03:22PM	Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
07:30AM	Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program PR Newswire
Apr-01-22 07:30AM	Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal PR Newswire
Mar-31-22 07:30AM	Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases PR Newswire
Feb-28-22 10:04AM	Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod Zacks
Feb-25-22 04:04PM	Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals Investor's Business Daily -8.87%
08:43AM	Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals Benzinga
08:25AM	Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM	BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS PR Newswire
06:59AM	Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment PR Newswire
06:55AM	Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences PR Newswire
06:50AM	Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb PR Newswire
Feb-24-22 06:20PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates Zacks
Feb-22-22 07:30AM	Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT PR Newswire
Feb-18-22 05:02PM	Will Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-16-22 07:30AM	BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022 PR Newswire
Feb-15-22 10:28AM	Biohaven (BHVN) Migraine Drug Meets Study Goals in China Zacks
Feb-14-22 09:05AM	Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints Benzinga
07:00AM	Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea PR Newswire
Feb-12-22 12:00PM	Hardware LDN Debuts Fall/Winter 2022 Collection PR Newswire
06:30AM	What to Expect From Biogen's $2.3 Billion Shopping Spree Motley Fool
Feb-10-22 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates Zacks
Feb-06-22 11:54PM	Were Hedge Funds Right About Biohaven Pharmaceutical Holding Company Ltd. (BHVN)? Insider Monkey
Feb-03-22 07:30AM	NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports PR Newswire
Feb-02-22 01:38PM	Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ... GuruFocus.com
Jan-29-22 11:07AM	Is This a Smart Deal for Pfizer? Motley Fool
Jan-25-22 07:30AM	Biohaven's Nurtec® ODT Extends Partnership with Rick Ware Racing for 2022 NASCAR Cup Series and NTT INDYCAR Series PR Newswire
Jan-10-22 12:01AM	Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain PR Newswire
Jan-08-22 06:30AM	Analysts' Revenue Estimates For Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Are Surging Higher Simply Wall St.
Jan-06-22 07:00AM	BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY PR Newswire +5.85%
Jan-05-22 07:00AM	Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States PR Newswire
Dec-13-21 11:38PM	Glenview Capital Management Buys Willis Towers Watson PLC, Uber Technologies Inc, Baxter ... GuruFocus.com
07:00AM	BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE PR Newswire
Dec-11-21 09:15AM	Biohaven Pharmaceutical Holding Co (BHVN) CFO James Engelhart Sold $3.6 million of Shares GuruFocus.com
Dec-09-21 10:57AM	Hedge Funds Are Piling Into Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Insider Monkey
Dec-08-21 07:38PM	Tekla World Healthcare Fund Buys Moderna Inc, Merck Inc, AstraZeneca PLC, Sells ResMed Inc, ... GuruFocus.com
07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... GuruFocus.com
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... GuruFocus.com
08:35AM	Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More Zacks
Dec-07-21 12:16PM	Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study Zacks
Dec-06-21 10:35AM	UPDATE 2-Biohaven's migraine therapy shows rapid pain relief in late-stage study Reuters
08:35AM	Biohaven's migraine therapy shows rapid pain relief in late-stage study Reuters
07:30AM	Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application PR Newswire
07:29AM	Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer PR Newswire
Nov-18-21 10:24AM	Notable Biohaven Pharma Hldgs Insider Trades $8.8M In Company Stock Benzinga
07:30AM	Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinsons Disease GlobeNewswire
Nov-17-21 06:57AM	NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine PR Newswire
Nov-15-21 08:00AM	Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital PR Newswire
Nov-11-21 11:44AM	Biohaven Pharma Hldgs Insider Makes $610K Stock Purchase Benzinga
07:44AM	The Zacks Analyst Blog Highlights: Regeneron, Moderna, Cassava Sciences, Biohaven Pharma and Pfizer Zacks
03:13AM	Traders Should Be Stopped Out of Biohaven Pharmaceutical TheStreet.com
Nov-10-21 12:53PM	Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data Zacks
09:43AM	Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal Zacks
Nov-09-21 04:07PM	Why Biohaven Pharmaceuticals Stock Crumbled On This Premium Deal With Pfizer Investor's Business Daily -12.91%
10:49AM	Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M Benzinga
08:55AM	Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q3 Loss, Tops Revenue Estimates Zacks

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Clark George C.	VP, Chief Accounting Officer	May 10	Option Exercise	53.76	2,250	120,960	8,265	May 12 08:58 PM
Clark George C.	VP, Chief Accounting Officer	May 10	Sale	141.50	4,200	594,300	4,065	May 12 08:58 PM
Clark George C.	VP, Chief Accounting Officer	Jan 19	Option Exercise	46.53	5,670	263,846	15,390	Jan 24 06:01 AM
Clark George C.	VP, Chief Accounting Officer	Jan 19	Sale	117.01	9,375	1,097,003	6,015	Jan 24 06:01 AM
Clark George C.	VP, Chief Accounting Officer	Jan 10	Option Exercise	0.00	1,000	0	10,184	Jan 12 09:12 PM
Stock Elyse	Chief Medical Officer	Jan 10	Option Exercise	0.00	937	0	5,374	Jan 12 09:10 PM
Mehta Kishan	Director	Jan 10	Option Exercise	0.00	1,875	0	10,640	Jan 12 09:04 PM
Coric Vlad	Chief Executive Officer	Jan 07	Option Exercise	0.00	10,000	0	42,218	Jan 07 09:16 PM
Engelhart James	Strategic Advisor	Jan 07	Option Exercise	0.00	3,250	0	16,952	Jan 07 09:17 PM
Stock Elyse	Chief Medical Officer	Jan 07	Option Exercise	0.00	1,000	0	4,437	Jan 07 09:17 PM
Stock Elyse	Chief Medical Officer	Jan 07	Option Exercise	0.00	3,250	0	12,629	Jan 07 09:17 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Jan 07	Option Exercise	0.00	3,750	0	15,630	Jan 07 09:16 PM
Tilton John	Chief Commercial Officer	Jan 07	Option Exercise	0.00	875	0	5,279	Jan 07 09:18 PM
Clark George C.	VP, Chief Accounting Officer	Jan 07	Option Exercise	0.00	1,000	0	9,706	Jan 07 09:18 PM
Gentile Kimberly	SVP, Clinical Operations	Jan 06	Option Exercise	0.00	3,750	0	13,453	Jan 07 09:17 PM
Conway Charles	Chief Scientific Officer	Jan 06	Option Exercise	0.00	3,750	0	23,935	Jan 07 09:18 PM
Clark George C.	VP, Chief Accounting Officer	Jan 06	Option Exercise	0.00	875	0	9,115	Jan 07 09:18 PM
Tilton John	Chief Commercial Officer	Jan 06	Option Exercise	0.00	1,250	0	4,955	Jan 07 09:18 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Jan 06	Option Exercise	0.00	5,000	0	14,110	Jan 07 09:16 PM
Stock Elyse	Chief Medical Officer	Jan 06	Option Exercise	0.00	1,250	0	3,437	Jan 07 09:17 PM
Stock Elyse	Chief Medical Officer	Jan 06	Option Exercise	0.00	3,750	0	11,217	Jan 07 09:17 PM
Engelhart James	Strategic Advisor	Jan 06	Option Exercise	0.00	3,750	0	15,234	Jan 07 09:17 PM
Coric Vlad	Chief Executive Officer	Jan 06	Option Exercise	0.00	12,500	0	38,072	Jan 07 09:16 PM
Buten Matthew	Chief Financial Officer	Dec 31	Option Exercise	0.00	12,500	0	12,500	Jan 04 09:30 PM
GREGORY JULIA P	Director	Dec 20	Option Exercise	23.63	12,000	283,560	12,000	Dec 22 09:51 PM
GREGORY JULIA P	Director	Dec 20	Sale	125.00	12,000	1,500,000	0	Dec 22 09:51 PM
Clark George C.	VP, Chief Accounting Officer	Dec 20	Sale	123.84	1,915	237,154	8,240	Dec 22 09:51 PM
Stock Elyse	Chief Medical Officer	Dec 15	Option Exercise	14.00	21,919	306,914	29,386	Dec 16 09:04 PM
Stock Elyse	Chief Medical Officer	Dec 15	Sale	105.49	21,919	2,312,127	7,467	Dec 16 09:04 PM
Stock Elyse	Chief Medical Officer	Dec 14	Option Exercise	15.65	6,939	108,599	14,406	Dec 16 09:04 PM
Stock Elyse	Chief Medical Officer	Dec 14	Sale	105.02	6,939	728,762	7,467	Dec 16 09:04 PM
Engelhart James	Chief Financial Officer	Dec 10	Option Exercise	0.00	35,000	0	46,196	Dec 10 08:43 PM
Engelhart James	Chief Financial Officer	Dec 10	Sale	102.55	35,000	3,589,146	11,196	Dec 10 08:43 PM
Doogan Declan	Director	Nov 29	Sale	112.80	24,525	2,766,433	870,648	Dec 01 07:24 PM
Clark George C.	VP, Chief Accounting Officer	Nov 26	Option Exercise	0.00	5,000	0	12,473	Nov 26 04:26 PM
Tilton John	Chief Commercial Officer	Nov 25	Option Exercise	0.00	1,250	0	3,909	Nov 26 04:33 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Nov 25	Option Exercise	0.00	3,000	0	10,127	Nov 26 04:32 PM
Stock Elyse	Chief Medical Officer	Nov 25	Option Exercise	0.00	3,375	0	9,066	Nov 26 04:33 PM
Engelhart James	Chief Financial Officer	Nov 25	Option Exercise	0.00	3,700	0	12,911	Nov 26 04:29 PM
Gentile Kimberly	SVP, Clinical Operations	Nov 25	Option Exercise	0.00	3,750	0	11,441	Nov 26 04:30 PM
Coric Vlad	Chief Executive Officer	Nov 25	Option Exercise	0.00	10,950	0	30,359	Nov 26 04:28 PM
Conway Charles	Chief Scientific Officer	Nov 25	Option Exercise	0.00	3,000	0	19,897	Nov 26 04:26 PM
Conway Charles	Chief Scientific Officer	Nov 23	Option Exercise	36.18	10,885	393,799	16,897	Nov 26 04:26 PM
Clark George C.	VP, Chief Accounting Officer	Nov 23	Option Exercise	32.42	1,915	62,084	7,473	Nov 26 04:26 PM
Doogan Declan	Director	Nov 16	Option Exercise	7.87	559,000	4,398,760	932,913	Nov 17 07:03 PM
Doogan Declan	Director	Nov 16	Sale	116.65	37,740	4,402,385	895,173	Nov 17 07:03 PM
CHILDS JOHN W	Director	Nov 15	Option Exercise	8.46	474,200	4,013,418	3,025,001	Nov 17 07:03 PM
CHILDS JOHN W	Director	Nov 10	Buy	122.87	5,000	614,342	2,550,801	Nov 10 06:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience